COMBACTE-NET Project Extended
We are delighted to share the Innovative Medicines Initiative (IMI)'s approval of the COMBACTE-NET project extension until 31 October 2023. This further underlines the importance of our projects in the fight against antimicrobial resistance and the level of commitment from IMI in supporting delivery of the project’s objectives.
Since 2013, COMBACTE-NET has been dedicated to building strong clinical, laboratory and research networks across Europe to enable more efficient clinical testing of novel antimicrobial drugs. These established networks represent the vital foundation on which COMBACTE and non-COMBACTE clinical trials have been performed over the last eight years.
These networks support the collection of data required for accurately identifying clinical needs and coming up with ideas for developing effective new antibacterial treatment options.
During the COVID-19 pandemic, scientists have been turning to the networks to identify sites for clinical trials of potential COVID-19 treatments. COMBACTE’s extensive, highly capable clinical and laboratory network is ensuring rapid participation of experienced hospital sites in COVID-19-focused clinical trials.
“The extension of COMBACTE-NET provides the extra time needed to complete important clinical research in the studies ASPIRE-ICU, ASPIRE-SSI, HONEST-PREPS, ARTHR-IS and EXPECT 1 & 2. It further supports the phase 3 study MICROCARE that is currently being set up but still needs the extension time now given to ensure complete clinical results. Results from all these studies will contribute significantly to fight the continuous battle against current and emerging multi-resistant bacteria.”
When setting up a clinical trial for a new antibiotic, one major challenge is finding enough patients with the study’s target bacterial infection.
COMBACTE-NET’s network of hospitals and laboratories across Europe are ready to participate in clinical trials that test novel antibiotics. So far, over 37,000 patients have been enrolled in the COMBACTE clinical trials and the first trials delivered initial results in 2016.
The continuation of these networks in the future would highly benefit society in the face of antimicrobial resistance, emerging infectious diseases and pandemics.
Related updates
Important Pieces Of A Puzzle
Reflections On COMBACTE-NET
